Mesoblast

Yahoo Finance • 10 days ago

Mesoblast (MESO) Sees Optimism From Analysts

We recently published 7 Best ASX Stocks to Buy Right Now.  Mesoblast Limited (NASDAQ:MESO) is one of the best ASX stocks. Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart fa... Full story

Yahoo Finance • 22 days ago

Mesoblast Participation at Piper Sandler Conference

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare... Full story

Yahoo Finance • last month

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational ov... Full story

Yahoo Finance • last month

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies i... Full story

Yahoo Finance • last month

Mesoblast Appoints James M O'Brien New CFO

(RTTNews) - Mesoblast Ltd. (MESO, MSB.AX), an Australian regenerative medicine company, Monday announced the appointment of James M O'Brien as its US-based Chief Financial Officer or CFO. The company said that the appointment was done as p... Full story

Yahoo Finance • last month

Mesoblast appoints James M. O’Brien as US-based CFO

[concept word CFO on metal blocks.close up of metal blocks,Business Concept.3D rendering on red background.] Mesoblast (MESO [https://seekingalpha.com/symbol/MESO]) has named [https://seekingalpha.com/pr/20309038-james-m-o-brien-appointed... Full story

Yahoo Finance • last month

James M. O’Brien Appointed Chief Financial Officer at Mesoblast

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully i... Full story

Yahoo Finance • 2 months ago

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug Administration (FDA) has scheduled... Full story

Yahoo Finance • 2 months ago

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ende... Full story

Yahoo Finance • 3 months ago

Mesoblast reports Q2 revenue surge of 66% on strong Ryoncil sales

* Mesoblast (OTCPK:MEOBF [https://seekingalpha.com/symbol/MEOBF]) reported US$21.9M in gross revenue for the quarter ended September 30, 2025. * This marks a 66% increase compared to the previous quarter. * Growth driven by strong sa... Full story

Yahoo Finance • 3 months ago

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil® (remestemcel-L-r... Full story

Yahoo Finance • 3 months ago

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HC... Full story

Yahoo Finance • 3 months ago

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured... Full story

Yahoo Finance • 3 months ago

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-r... Full story

Yahoo Finance • 4 months ago

Mesoblast enters option to issue $50M convertible notes

* Mesoblast (OTCPK:MEOBF [https://seekingalpha.com/symbol/MEOBF]) entered into convertible note [https://seekingalpha.com/pr/20220508-mesoblast-enters-into-option-to-issue-us-50-million-convertible-notes] subscription agreements with Sur... Full story

Yahoo Finance • 4 months ago

Mesoblast Secures Up To US$50 Mln In Convertible Note Agreements With Key Investors

(RTTNews) - Mesoblast Limited (MESO, MSB.AX) announced that it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck, to issue up to US$50... Full story

Yahoo Finance • 4 months ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements... Full story

Yahoo Finance • 4 months ago

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period end... Full story

Yahoo Finance • 5 months ago

Mesoblast Limited (MESO) Launches First Cell Therapy for Children

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Mesoblast Limited stands tenth on our list and has launched the first cell therapy for children. Mesoblast Limited (NASDAQ:MESO) is among the best mid... Full story

Yahoo Finance • 5 months ago

Jefferies downgrades Mesoblast stock to Hold despite price target increase

Investing.com - Jefferies downgraded Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) from Buy to Hold while raising its price target to AUD2.60 from AUD2.50. Despite the downgrade, InvestingPro data shows MESO has delivered an impressive 73.8%... Full story